SEC Tracker
Get the app

Keros Therapeutics KROS

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Form
8-K
Filed
Importance
Routine
  • Reports an executive or board change (5.02)
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  2. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025